TAIWAN BIOTECH CO., LTD.

TAIWAN BIOTECH CO., LTD.

Previous company name

Name change date

Company Overview
This privately-owned company is engaged in the research and development, manufacturing, and distribution of modern medicine, active pharmaceutical ingredients, medical equipment, oral and optical drugs and equipment supplies, biotech formulations and health food, traditional Chinese herbal medicine and related import/export operations. The company was established in 1962 and has its registered office in Taoyuan, Taiwan.
The company has five plants in Taiwan –the Taoyuan plant, Biotech production plant, Taoyuan API plant, Kuan Yin plant, and Veterans Pharmaceutical plant. Its Taoyuan plant encompasses an expansive 324,000 square-foot facility that houses four production plants including the parenteral plant, BFS (Blow-Fill-Seal) parenteral plant, solid product manufacturing plant and TDDS (Transdermal Drug Delivery System) plant. The company’s Biotech Production Plant in the Hsinchu Science-based Industrial Park is focused on the research and development of health beneficial biotech foods and Chinese herbal medicine. The Taoyuan API Plant primarily produces Cephalosporin antibiotics and intermediate, noticeably of the Cephalexin that has been certified by the U.S. FDA in 1994. The Kuan Yin plant provides cephalosporin products in form of tablets, capsules, and injections which support the company’s Taoyan main plant in mapping out a comprehensive product portfolio. The Veterans Pharmaceutical plant mainly supplies gastrointestinal and respiratory treatment drugs, and skin improvement products.
Since 1996, the company has installed a global trading enterprise development division in charge of promoting export of house products and its operations over the years has yielded a dynamic sales network of steady growth across Japan, Southeast Asia, mainland China, and North America. With expectation for the future, the company continues expanding its pharmaceutical products to world markets and takes a two-way exchange of innovative foreign biotech know-how and fine products to excel its R&D know-how and improve its overall competitiveness.
Business Summary
The Company’s main activities are consist of research and development, manufacturing, representation and sales distribution of modern medicine, active pharmaceutical ingredients, medical equipment, oral and optical drugs and equipment supplies, biotech formulations and health food, traditional Chinese herbal medicine and related import/export operations.
Description and history
The Company was establish on October 9, 1962. The Company was listed on Public Companies on March 14, 1987. The Company’s main activities are consist of research and development, manufacturing, representation and sales distribution of modern medicine, active pharmaceutical ingredients, medical equipment, oral and optical drugs and equipment supplies, biotech formulations and health food, traditional Chinese herbal medicine and related import/export operations.

Milestones:

1945
Company predecessor, Glucose Corporation, instilled.

1962
Company reorganized as Sintong Chemical Industry Company, Limited with $35 million paid-in capitalization as an integrated local pharmaceutical producer.

1979
20ml BFS filler machine procured marking the firm as a premiere local SVP small volume parenteral producer.

1987
Paid-in capitalization upped to $200 million with IPO completed and passed GMP Good Manufacture Practice inspection.
Representation of Japan’s Nikkiso hemodialysis equipment as the agency embarked on the medical treatment equipment and related field.
Exports reaching Vietnam to excel Sintong in global expansion.
Full computerization inducted.

1988
Launched the first bio-equivalent test product in Taiwan, Ranidine, formally certified by the Department of Health.

1989
Addition of 20ml BFS filling machine.
Investment in Taiwan Biotech Co., Ltd offering upstream Active Pharmaceutical Ingredients (APIs).

1990
Technical pact with the Japanese Eisai in jointly producing Aminol-K and the presentation of many of its related products.
Joint development of transdermal delivery drug system (TDDS) with an U.S.A. Pharmaceutical Development company.

1992
Accredited with Outstanding Award in the first Outstanding Biotech Awards by the Ministry of Economic Affairs.
Bestowed with a pilot new product R&D plan for transdermal products sanctioned by the Ministry of Economic Affairs’ Bureau of Industrial Development.

1993
Accredited with an Outstanding Award by the ROC Biotech Industry Development Council.
Branch office launched at the Hsinchu Science-based Industrial Park.

1994
Curie Chemicals and Pharmaceuticals Manufacturing Co., Ltd’s plant joined Taiwan Biotech’s production line in producing oral products.
The addition of 10ml BFS filler machine.
API plant certified by the U.S. Food & Drug Administration.

1995
Innovative transdermal nicotine patch, Smokfree, debuted.

1996
AnPo, a labour inhibitors, debuted.

1997
Export of a 20ml BFS Bill-Flow-Seal to Japan began

1998
Dynamics Venture Capital formed in a move to integrate the company’s venture investments.

1999
Represent the U.S. pharmaceutical company, Ocular Sciences’ contact lenses.
Sales and marketing of respiratory system medical equipment, began.
Investments made to the U.S. company, Optics Corporation, through which TBC’s products started to export to the U.S.

2001
Renamed as Taiwan Biotech Company, Limited.
Represent the U.S. pharmaceutical company, Cephalon’s Provigil- a narcolepsy treatment solution.
Implemented and surpassed the cGMP phase-one review.

2002
Biotech food manufactory launched at the Hsinchu Science-based Industrial Park.
Strategic alliance formed with Fresenius Medical Care Corporation of Germany.

2003
Implemented and surpassed the cGMP(II)-process validation review.

2004
Accredited with pharmaceutical technology research award in the third pharmaceutical technology research awards by the department of health executive yuan.
Accredited with orphan drug research award in the third orphan drug research awards by the department of health executive yuan.

2005
Implemented and surpassed the cGMP(III)-computer validation review.
Accredited with pharmaceutical technology research award in the forth pharmaceutical technology research awards by department of health executive yuan.
Eye-Cept Rewetting Drops got FDAs approval of 510(k) for contact lens care products in USA.
Purchasing the Kuan Yin plant of Fujisawa Pharmaceutical Co., Ltd in Taiwan.
Acquired management authority of The Veterans Pharmaceutical Plant.

Business Line
Engaged in the research and development, manufacturing, and distribution of modern medicine, active pharmaceutical ingredients, medical equipment, oral and optical drugs and equipment supplies, biotech formulations and health food, traditional Chinese herbal medicine and related import/export operations
Subsidiary
AMPHASTAR PHARMACEUTICALS, INC.
Advisor
FIRST HORWATH & C OMPANY,CPAS
IPO date
3/14/1987
US SIC Code
2834
Company Address
22, Jie-Shou Road

City province or state postal code
TAOYUAN
Phone: +886 03 361 2131
Fax: +886 03 367 0029
Country address: TAIWAN
Website url: www.sintong.com